Oscars 2026 red carpet reignites debate over GLP-1 weight-loss drugs in Hollywood

The March 15 Academy Awards red carpet became the setting for a renewed argument about GLP-1 weight-loss drugs, with India Today and Times Now both asking whether Hollywood has pushed their use too far ^[1][2]. Both outlets described a night dominated by very thin bodies and hollowed cheeks, and both named actors who have not said publicly whether they take the medications.

India Today wrote that alongside the feathered gowns and archival fashion, "an overwhelming uniformity of extremely slender bodies and remarkably sunken cheeks" stood out at the Dolby Theatre in Los Angeles ^[1]. The outlet named Demi Moore, Emma Stone and Nicole Kidman, and also Barbie Ferreira, Kathy Bates and Melissa McCarthy ^[1]. Times Now ran a similar list, describing a return of 1990s "heroin chic" — "protruding cheekbones, visible rib cages, stick-thin arms" ^[2].

Neither report states that any of those actors uses a GLP-1 drug, and no comment from them about the speculation appears in either article ^[1][2]. India Today noted one exception to the pattern of silence: Oprah Winfrey has openly acknowledged using a GLP-1 medication for weight loss, which the outlet raised in connection with her appearance at Paris Fashion Week earlier in March ^[1]. The same report pointed to Anya Taylor-Joy at a pre-Oscars dinner on March 12 as another appearance that set off online discussion ^[1].

Reaction on social media was part of the coverage. India Today quoted a user on X: "So many people are just skin and bones. Husks of their former gorgeous selves. Shame, really. I understand its use since many people struggle with weight loss, but it can be used in measured ways. This seems excessive" ^[1]. Times Now noted that Stone had drawn similar commentary at an earlier awards event, and that Moore, 63, was criticized over her appearance at a Dior fashion show ^[2].

What doctors quoted in the coverage warn about

Times Now reported that drugs including Ozempic and Wegovy, which are semaglutide, and Mounjaro, which is tirzepatide, were developed to treat type 2 diabetes and work by mimicking hormones that regulate blood sugar and appetite, slowing stomach emptying and reducing hunger ^[2]. Doctors told the outlet that off-label use for cosmetic weight loss is not risk-free ^[2].

Commonly reported side effects listed in that report include nausea, vomiting, diarrhea, constipation and severe abdominal pain ^[2]. Less common but more serious complications mentioned include pancreatitis, gallbladder disease and severe gastrointestinal problems ^[2]. Doctors also warned about muscle loss and nutritional deficiencies when the drugs are misused or taken without dietary guidance, and about "Ozempic face," a term for facial volume loss after rapid weight loss ^[2].

Times Now also reported that the surge in demand has contributed to supply shortages in recent years, raising concern among doctors that people with diabetes who rely on the medication could have trouble filling prescriptions ^[2]. Public health experts quoted in the article said the drugs are intended for people with obesity or diabetes who meet specific clinical criteria and should be taken under a qualified health care provider's supervision ^[2].

Neither report provides prescribing data, sales figures, or any study linking red-carpet appearances to GLP-1 use. What any individual actor is taking has not been disclosed ^[1][2].

Why it matters for patients

Coverage like this tends to blur two different things: a prescription written for a person who meets clinical criteria, and off-label use for appearance ^[2]. The doctors quoted in the Times Now report treat those as separate questions, and their concerns — gastrointestinal side effects, muscle loss, nutrition and supply — apply mainly to the second ^[2].

Shortages have a practical edge. If demand for weight-loss prescribing squeezes supply, patients using the drugs for blood sugar control can be affected at the pharmacy counter ^[2]. That concern is described in general terms; no current shortage figures or dates appear in the reports ^[2].

Public speculation about a celebrity's body is not medical information. The Oscars coverage names people who have not said whether they use these drugs, and the articles do not establish it ^[1][2]. For readers weighing their own treatment, the reporting offers no new clinical findings about semaglutide or tirzepatide — only a cultural argument about how thin is too thin ^[1][2].